Hims & Hers makes a big Europe push with an acquisition. Knockoff weight loss drugs could be next
Hims & Hers (HIMS) is expanding its playbook across the Atlantic — the U.S.-based telehealth company announced Tuesday that it will acquire European telehealth platform Zava. The acquisition grows Hims & Hers’ presence in the U.K. and gives the company a foothold in Germany, France, and Ireland, marking the company’s…Read more... [...]
Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
Hims & Hers stock tumbles as the FDA issues a warning about 'unapproved' weight loss drugs
Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company braces for big regulatory shifts in the weight-loss drug industry.Read more. [...]
Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 market — which is projected to hit $105 billion by 2030, according to Morgan S [...]
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
London-headquartered biotech startup Verdiva has emerged from stealth with a whopping $410mn for a new range of drugs aimed at tackling the obesity epidemic. It’s one of Europe’s largest-ever biot [...]
